GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES-A REVIEW
Reshma Ramesan* and Dr. Sruthy Renjan
Targeting the incretin system has become an important therapeutic approach for treating type 2 diabetes. In people with type 2 diabetes mellitus (T2DM), the incretin effect is reduced, but the recent advent of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide (GLP)-1 agonists/analogues has enabled restoration of at least some of the function of the incretin system, with accompanying improvements in glycaemic control. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. Two GLP-1 receptor agonists/analogues are currently approved for the treatment of T2DM— exenatide (Byetta®, Eli Lilly & Co., Indianapolis, IN, US) and liraglutide (Victoza®, Novo Nordisk, Bagsvaerd, Denmark); a once-weekly formulation of exenatide (Bydureon®, Eli Lilly & Co.) has also been approved by the European Medicines Agency. This review aims to investigate the effectiveness of GLP-1 analogues in patients with type 2 diabetes mellitus who are not achieving satisfactory glycaemic control with one or more oral glucose lowering drugs.[1,2]
Keywords: Targeting the incretin system has become an important therapeutic approach for treating type 2 diabetes.
[Full Text Article]